NEW YORK STOCK EXCHANGE, INC. · ADCT
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
ADC Therapeutics SA

ADC Therapeutics SA

Biotechnology
$1.13
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
ADCT
ADC Therapeutics SA
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

43/ 100
Veridion Score
SELL BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ADCT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ADCT catalysts
About ADC Therapeutics SA
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
193
Country
CH

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.13
Last session
Day high
$1.13
Last session
Day low
$1.13
Last session
Previous close
$1.13
52W high
$4.88
-76.84% from high
52W low
$0.9777
4% of range
Market cap
$143.7M
EPS
$-1.3700
Beta
1.09
Shares out
127.2M
Avg volume
1.2M
VWAP
$1.13
Last session
Price history computed in-house
1W
+7.62%
1M
-12.40%
3M
-67.06%
1Y
-57.84%
YTD
-67.99%
SMA 50 $1.36 · below
SMA 200 $3.27 · below
52W position 4%

ADCT overview

Veridion Score
43
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ADCT.Congress disclosuresOpen receipt and filing context for ADCT.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ADCT Form 4 filings
Public disclosures

Congress activity in ADCT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ADCT in the cached public ledger.

Federal contracts

ADCT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ADCT in this window.
Lobbying spend

ADCT lobbying filings, year to date.

Registered lobbying filings matched to ADC Therapeutics SA.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ADCT in this window.
Loading news for ADCT
Analyst ratings
Sovereign unlock shows live analyst consensus for ADCT.
Options
Sovereign unlock shows live options positioning for ADCT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.